<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45316">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025426</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032812</org_study_id>
    <nct_id>NCT02025426</nct_id>
  </id_info>
  <brief_title>Phenylephrine Versus Ephedrine in Pre-eclampsia</brief_title>
  <official_title>Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenylephrine administration is associated with reductions in CO and SctO2 compared with
      ephedrine when used for blood pressure management in women with pre-eclampsia undergoing
      cesarean delivery under spinal anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cerebral tissue oxygen saturation</measure>
    <time_frame>Intraoperative from spinal placement till 10 min after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Intraoperative from spinal placement till 10 min after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in umbilical artery pulsatility index measured by ultrasound following initiation of spinal anesthesia</measure>
    <time_frame>Intraoperative from spinal placement till 10 min after spinal</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal umbilical cord gases and lactates</measure>
    <time_frame>Within 5 minutes after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Intraoperative hypotension</measure>
    <time_frame>Intraoperatively from spinal placement till 10 minutes after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Intraoperative nausea and vomiting</measure>
    <time_frame>Intraoperatively from time of spinal placement until end of surgery.</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Changes in uterine artery pulsatility index measured by ultrasound following initiation of spinal anesthesia</measure>
    <time_frame>Intraoperatively from spinal placement to 10 min after spinal</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine for maintaining blood pressure within 10 % of baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ephedrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ephedrine for maintaining blood pressure within 10 % of baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <arm_group_label>Phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <arm_group_label>Ephedrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

          -  Age â‰¥18 yrs

          -  Pre-eclampsia (mild, or severe)

          -  Non-laboring women

          -  CD under spinal anesthesia

        Exclusion Criteria:

          -  Height &lt; 5'0&quot;

          -  Allergy to phenylephrine or ephedrine, or any other standardized medication

          -  Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class
             III and IV)

          -  Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

          -  History of recent amphetamine or cocaine use.

          -  Subject enrollment in another study involving a study medication within 30 days of CD

          -  Any other physical or psychiatric condition which may impair their ability to
             cooperate with study data collection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf S Habib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashraf S Habib, MD</last_name>
    <phone>919-668-6266</phone>
    <email>habib001@mc.duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf S Habib, MD</last_name>
      <phone>919-668-6266</phone>
      <email>habib001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Ashraf S Habib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 30, 2013</lastchanged_date>
  <firstreceived_date>December 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cesarean delivery</keyword>
  <keyword>Spinal Anesthesia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
